IDT Australia Limited Stock price

Equities

IDT

AU000000IDT0

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.077 AUD -3.75% Intraday chart for IDT Australia Limited -2.53% -30.00%
Sales 2022 12.13M 7.92M Sales 2023 7.03M 4.59M Capitalization 23.76M 15.5M
Net income 2022 -1M -653K Net income 2023 -8M -5.22M EV / Sales 2022 1.6 x
Net cash position 2022 8.33M 5.44M Net cash position 2023 3.69M 2.41M EV / Sales 2023 2.85 x
P/E ratio 2022
-23 x
P/E ratio 2023
-1.87 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 80.61%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.75%
1 week-2.53%
Current month-15.38%
1 month-17.20%
3 months-26.67%
6 months+26.23%
Current year-30.00%
More quotes
1 week
0.08
Extreme 0.077
0.08
1 month
0.08
Extreme 0.077
0.10
Current year
0.08
Extreme 0.077
0.11
1 year
0.05
Extreme 0.05
0.13
3 years
0.05
Extreme 0.05
0.76
5 years
0.05
Extreme 0.05
0.76
10 years
0.05
Extreme 0.05
0.76
More quotes
Managers TitleAgeSince
Chief Executive Officer - 20-12-31
Director of Finance/CFO - 22-09-27
Human Resources Officer - 21-08-31
Members of the board TitleAgeSince
Chairman 54 22-10-09
Director/Board Member - 22-10-09
Director/Board Member 65 22-01-27
More insiders
Date Price Change Volume
24-03-28 0.077 -3.75% 44,183
24-03-27 0.08 +1.27% 51,825
24-03-26 0.079 -1.25% 74,780
24-03-25 0.08 0.00% 84,571
24-03-22 0.08 +1.27% 115,744

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. Its business includes research and development, active pharmaceutical ingredient (API) and finished dosage form manufacture (FDF), clinical and commercial, project management, chemical services, analytical chemistry, pharmacy services, pharmaceutical development in all dosage forms, clinical packaging and regulatory affairs services. Its Current Good Manufacturing Practice (cGMP) manufacturing facilities can produce both API and FDF positioning it as a facility in the medicinal cannabis manufacturing space. It also provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms. Its analytical laboratories offer medicinal cannabis cGMP testing.
More about the company
  1. Stock
  2. Equities
  3. Stock IDT Australia Limited - Australian S.E.